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Abstract
Background and Objective: Curcuma longa  (C. longa)  extract has been reported as a potent anti-inflammatory agent. The main objective
of this study was to evaluate the effectiveness of Curcuma longa extract to decrease Tumor Necrosis Factor-alpha (TNF-") and cells
damage prevention in early pregnant mice with acute toxoplasmosis. Materials and Methods: This study evaluated 20 early pregnant
mice. The mice were divided into five groups (G1-G5). G1-G4 were injected with 10  tachyzoites of Toxoplasma gondii  and G5 was not
injected. Three days later, G1 and G2 were intervened with C. longa  extract dose of 125 mg and 500 mg kgG1/day, respectively. G3 was
a positive control and G4 was a negative control. G5 was not intervened. The TNF-" level was examined serially (before and 3 days post
tachyzoites injection and 3 and 7 days post-intervention). The placental mice were taken 7 days after intervention for histopathology
examination. Results: The TNF-" level increased significantly 3 days after tachyzoites injection (p<0.05) and TNF-" level decreased
significantly 3 and 7 days after curcuma longa intervention compared to the negative control (p<0.05). Hemorrhagic and necrotic cells
were not found in the group intervened with C. longa extract but it found in the positive and negative control groups were 75 and 100%,
respectively. Conclusion: Curcuma longa is effective to suppress TNF-" level and prevent placental cells damage in early pregnant mice
with acute toxoplasmosis.
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INTRODUCTION
Toxoplasmosis is a zoonotic disease caused by
Toxoplasma  gondii 1,2.  It  can  cause abortion  if the infection
happens during early pregnancy3,4. The abortion caused by
Toxoplasma  gondii  (T.  gondii)  not  only caused by direct
effect   of     parasites    but    can    occur    due   to excessive
pro-inflammatory reaction. Toxoplasma gondii will trigger
antibody (anti-toxoplasma IgG-IgM   anti-body)5,6  and  cellular
immunity (TNF-")7,8. The excessive TNF-" levels reported can
cause intravascular thrombosis, ischemic and necrotic cells.
The increased of TNF-" levels due to Toxoplasma gondii
infection in early pregnancy can lead to abortion9.
Serranti et al.10 reported that until now, there has been no
ideal drug for toxoplasmosis therapy in pregnant women10.
Spiramycin is still the drug of choice but it has been proven
unable to eradicate infection in the fetus. Early pregnancy with
acute T. gondii  infection may be treated with spiramycin11.
The therapy with spiramycin will kill the parasite because it
works as a bactericidal but spiramycin unable to inhibit the
inflammatory process. The abortion caused by T. gondii
infection is not only due to the direct effects of the parasite
but it can also result from excessive inflammatory responses
leading to abortion9,12.
Curcuma longa  has   been   shown   to   have   potent
anti-inflammatory13-15 and anti-bacterial, anti-parasites but
more likely to be anti-inflammatory15-17. Curcumin is the main
content of C. longa, it has  been  shown  to suppress TNF-"13-15.
There was  no  study conducted which evaluate the C. longa
effect on the toxoplasmosis18. Hence, this study aimed to
determine the effectiveness of C. longa extract compared to
spiramycin, especially in preventing cell damage on early
pregnant mice with acute toxoplasmosis by analyzing levels
of TNF-" and histopathology examination of placental tissue.
MATERIALS AND METHODS
This study   was   carried   out   from  February, 2017-
September, 2017 in Molecular Biology and Immunology
Laboratory, Faculty of Medicine, Hasanuddin University,
Makassar, Indonesia.
Subjects: The study was conducted on 20 Balb/c female mice
that were conditioned into 1-3 day(s) pregnancy that fulfill
inclusion criteria (mice age 11-13 weeks, weigh 16- 20 g, active
movement, no physical defect and willing to eat and drink).
The early pregnant mice were divided into five groups (G1-G5)
randomly,  4  mice  each  group.  G1-G4  were  injected  with
10 tachyzoites of T. gondii   RH   strain   intra-peritoneal  and
G5 without infection. At the end of the study, the mice were
sacrificed then buried in specified places. This research has
been approved by the animal ethics research committee of
the Faculty of Medicine, University of Hasanuddin, Makassar,
Indonesia  (Number: 535/114.8.4.5.31/PP36-KOMITEK/20160),
dated 2 May, 2016.
Preparation and modeling of experimental animals: Mice
were conditioned  into pregnancy by bringing together
female and male mice in one cage. Every morning, signs of
pregnancy were evaluated in the form of a plug in the vagina
(reddish and swollen vagina). If plug is found, the mice were
considered  pregnant  and  the  gestational  age is day 0. The
C. longa extract use was obtained by maceration and the
curcuminoid compound was evaluated using KLT
densitometry  and  spectrophotometry. Curcuminoid level in
C. longa  extract obtained were at 25.5%.Tachyzoites used in
this study were from the T. gondii strain RH (strain pathogen;
SRA: ERS670498).
Intervention of experimental animals: Three days after
injection   of    tachyzoites,    G1   and   G2   were   each  given
C. longa extract dose of 125 and 500 mg kgG1/day,
respectively, G3 (positive control) was given spiramycin dose
of 60 mg kgG1/day and G4 (negative control/placebo) was
given 0.2 mL distilled water. Each intervention was
administered orally using cannulas for 7 days. G5 was not
infected nor intervened with.
Taking and examination of sample: Blood samples were
taken from the tail vein serially (1 day before tachyzoites
injection, 3 days after tachyzoites injection, 3 and 7 days after
the intervention). Examination of anti-toxoplasma IgG-IgM
antibody  levels  and TNF-" level were examined using
Enzyme-Linked Immunosorbent Assay (ELISA).
Seven days after the intervention, the mice were
sacrificed by breaking the cervical vertebrae and then surgery
was performed to remove the uterus containing the placenta.
Examination of placental histopathology in all samples was
done to study and assessed the degree of damage of placental
tissue in the form of the congestive capillary, extracellular
edema, hemorrhagic and necrotic cells, all of which were
histopathology findings.
Statistical analysis: The data obtained were statistically
analyzed using paired t-test to determine the TNF-" level
before  and   after   intervention.   One-way   ANOVA   test  was
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conducted to determine the difference of TNF-" level
between the five groups. Histopathology presentation was
reported in percentage and chi-square test was performed to
identify cells damage between groups. The p<0.05 is used.
RESULTS
The results of TNF-" level are reported in Table 1. The
TNF-" level increased significantly 3 days after tachyzoites
injection (p<0.05). Three  and 7 days  after  intervention with 
C. longa  extract  dose  of 125 mg kgG1/day, C. longa dose of
500 mg kgG1/day and spiramycin dose of 60 mg kgG1/day, the
TNF-" level decreased significantly (p<0.05) (Table 2). The
decrease of TNF-" level among the three groups (G1-G3) was
not significant (Table 3 and 4). The TNF-" level in negative
control (G4) increased significantly during the study, while in
the non-infected group (G5), TNF-" level during the study
fluctuated insignificantly (p>0.05) (Table 2).
The  results of the histopathology presentation are shown
in  Fig.  1.  Hemorrhagic  and  necrotic  cells  were  not present
Table 1: TNF-" level before and after the injection of tachyzoites and post-intervention
 TNF-" level (pg mLG1)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Groups (G) A  B C  D
G1 36.738±0.015 301.708±0.025 130.230±0.013 81.976±0.010
G2 31.310±0.013 285.244±0.018 144.102±0.013 88.610±0.015
G3 38.219±0.013 305.425±0.017 137.139±0.013 85.870±0.013
G4 35.814±0.013 292.432±0.020  352.750±0.019 558.436±0.020
G5 36.517±0.008  36.517±0.007  34.410±0.010 36.517±0.005
Groups G1-G4: Early pregnant mice were injected tachyzoites. Interventions: G1 and G2 (mice given C. longa extract dose of 125 and 500 mg kgG1/day, respectively),
G3 (positive control and G4 (negative control/placebo), each group is administered for 7 days, G5 (normal group). Blood sampling times: A (1 day before tachyzoites
injection), B (3 days after tachyzoites injection), C (3 days after the intervention) and D (7 days after the intervention)
Table 2: Statistic analysis of TNF-" levels before and after intervention
Paired differences
----------------------------------------------------------------------------------------------------
95% confidence interval 
of the difference
Standard Standard ----------------------------------- Significant
Groups Pairs Mean deviation error mean Lower Upper T df (2-tailed)
G1
1 TNFA-TNFB -244.886 29.516 14.758 -291.853 -197.918 -16.593 3 0.000
2 TNFB-TNFC 151.395 32.985 16.492 98.907 203.882 9.179 3 0.003
3 TNFB-TNFD 199.648 32.749 16.374 147.537 251.759 12.193 3 0.001
4 TNFC-TNFD 48.253 33.948 16.974 -5.766 102.273 2.843 3 0.066
G2
1 TNFA-TNFB -253.934 23.004 11.502 -290.539 -217.328 -22.076 3 0,000
2 TNFB-TNFC 141.141 15.573 7.786 116.360 165.922 18.126 3 0,000
3 TNFB-TNFD 196.633 16.540 8.270 170.314 222.951 23.777 3 0,000
4 TNFC-TNFD 55.491 12.917 6.458 34.936 76.046 8.592 3 0.003
G3
1 TNFA-TNFB -267.206 38.065 19.032 -327.778 -206.635 -14.039 3 0.001
2 TNFB-TNFC 168.286 26.750 13.370 125.719 210.852 12.582 3 0.001
3 TNFB-TNFD 219.555 3.409 1.704 214.130 224.981 128.784 3 0.000
4 TNFC-TNFD 51.269 30.029 15.010 3.485 99.053 3.415 3 0.042
G4
1 TNFA-TNFB -256.617 43.327 21.663 -325.560 -187.673 -11.846 3 0.001
2 TNFB-TNFC -60.318 31.887 15.943 -111.057 -9.578 -3.783 3 0.032
3 TNFB-TNFD -266.003 58.518 29.259 -359.118 -172.888 -9.091 3 0.003
4 TNFC-TNFD -205.685 57.951 28.975 -297.899 -113.470 -7.098 3 0.006
G5
1 TNFA-TNFB 0 5.131 2.565 -8.164 8.166 0 3 1.000
2 TNFB-TNFC 2.107 5.319 2.659 -6.356 10.571 0.792 3 0.486
3 TNFB-TNFD 0 7.255 3.627 -11.544 11.544 0 3 1000
4 TNFC-TNFD -2.107 3.535 1.767 -7.733 3.518 -1.192 3 0.319
Groups: G1 and G2 (mice given C. longa extract dose of 125 and 500 mg kgG1/day  respectively), G3 (positive control), G4 (negative control/placebo), G5(Normal group).
Tumor Necrosis Factor (TNF), TNFA (TNF-" levels 1 day before tachyzoites injection), TNFB (TNF-" levels 3 days after tachyzoites injection), TNFC (TNF-" days 3 after
the intervention) and TNFD (TNF-" levels 7 days after the intervention) (p<0.05)
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Fig. 1: Histopathology presentation of placental tissue sort by group (G1-G5). G1-G4 were injected 10 tachyzoites to
intra-peritoneal space. Interventions: G1 and G2 (mice given C. longa extract dose of 125 and 500 mg kgG1/day
respectively), G3 (positive control), G4 (negative control/placebo), 7days each and G5 (normal group)
Table 3: Statistic analysis of TNF-" levels after 3 days intervention among five groups
95% confidence interval
Dependent Mean Standard -------------------------------------------
variable (I) Groups (J) Groups difference (I-J) error Significant Lower bound Upper bound
TNFC Curcumin (125 mg) Curcumin (500 mg) -13.873000 14.421981 0.868 -58.40699 30.66099
Spiramycin (60 mg) -6.909750 14.421981 0.988 -51.44374 37.62424
Placebo -222.521000* 14.421981 0.000 -267.05499 -177.98701
Normal 95.819500* 14.421981 0.000 51.28551 140.35349
Curcumin (500 mg) Curcumin (125 mg) 13.873000 14.421981 0.868 -30.66099 58.40699
Spiramycin (60 mg) 6.963250 14.421981 0.988 -37.57074 51.49724
Placebo -208.648000* 14.421981 0.000 -253.18199 -164.11401
Normal 109.692500* 14.421981 0.000 65.15851 154.22649
Spiramycin (60 mg) Curcumin (125 mg) 6.909750 14.421981 0.988 -37.62424 51.44374
Curcumin (500 mg) -6.963250 14.421981 0.988 -51.49724 37.57074
Placebo -215.611250* 14.421981 0.000 -260.14524 -171.07726
Normal 102.729250* 14.421981 0.000 58.19526 147.26324
Placebo Curcumin (125 mg) 222.521000* 14.421981 0.000 177.98701 267.05499
Curcumin (500 mg) 208.648000* 14.421981 0.000 164.11401 253.18199
Spiramycin (60 mg) 215.611250* 14.421981 0.000 171.07726 260.14524
Normal 318.340500* 14.421981 0.000 273.80651 362.87449
Normal Curcumin (125 mg) -95.819500* 14.421981 0.000 -140.35349 -51.28551
(no intervention) Curcumin (500 mg) -109.692500* 14.421981 0.000 -154.22649 -65.15851
Spiramycin (60 mg) -102.729250* 14.421981 0.000 -147.26324 -58.19526
Placebo -318.340500* 14.421981 0.000 -362.87449 -273.80651
TNFC: TNF-" levels after 3 days intervention, p<0.05
in the group   intervened   with   C.   longa  extract   dose  of
125 mg kgG1/day and dose of 500 mg kgG1/day but in the
group intervened with spiramycin, 75% of the samples
obtained had hemorrhagic and necrotic cells and in the
negative  control  group,  the  hemorrhagic  and  necrotic
features were obtained in all samples (100%). The occurrence
of hemorrhagic and necrotic cells between C. longa and
spiramycin  intervention  were   significantly   different
(p<0.05).
DISCUSSION
In  this  study,  3  days after the injection of tachyzoites,
the anti-toxoplasma IgG-IgM antibody levels increased
significantly.    Increased   levels  of anti-toxoplasma IgG-IgM
antibodies in this study proves that mice in this study have
occurred acute toxoplasmosis. Simanjuntak et al.6 reported
that injecting 10 tachyzoites intra-peritoneal in mice during
early  pregnancy  caused  the  anti-toxoplasma  IgM  antibody
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Table 4: Statistic analysis of TNF-" levels after 7 days intervention among five groups
95% confidence interval
Dependent Mean Standard -------------------------------------------
variable (I) groups (J) groups difference (I-J) error Significant Lower bound Upper bound
TNFD Curcumin (125 mg) Curcumin (500 mg) -6.635000 16.050344 0.993 -56.19725 42.92725
Spiramycin (60 mg) -3.893750 16.050344 0.999 -53.45600 45.66850
Placebo -476.459750* 16.050344 0.000 -526.02200 -426.89750
Normal 45.458500 16.050344 0.080 -4.10375 95.02075
Curcumin (500 mg) Curcumin (125 mg) 6.635000 16.050344 0.993 -42.92725 56.19725
Spiramycin (60 mg) 2.741250 16.050344 1.000 -46.82100 52.30350
Placebo -469.824750* 16.050344 0.000 -519.38700 -420.26250
Normal 52.093500* 16.050344 0.037 2.53125 101.65575
Spiramycin (60 mg) Curcumin (125 mg) 3.893750 16.050344 0.999 -45.66850 53.45600
Curcumin (500 mg) -2.741250 16.050344 1.000 -52.30350 46.82100
Placebo -472.566000* 16.050344 0.000 -522.12825 -423.00375
Normal 49.352250 16.050344 0.051 -0.21000 98.91450
Placebo Curcumin (125 mg) 476.459750* 16.050344 0.000 426.89750 526.02200
Curcumin (500 mg) 469.824750* 16.050344 0.000 420.26250 519.38700
Spiramycin (60 mg) 472.566000* 16.050344 0.000 423.00375 522.12825
Normal 521.918250* 16.050344 0.000 472.35600 571.48050
Normal Curcumin (125 mg) -45.458500 16.050344 0.080 -95.02075 4.10375
(No intervention) Curcumin (500 mg) -52.093500* 16.050344 0.037 -101.65575 -2.53125
Spiramycin (60 mg) -49.352250 16.050344 0.051 -98.91450 0.21000
Placebo -521.918250* 16.050344 0.000 -571.48050 -472.35600
TNFD: TNF-" levels after 7 days intervention, p<0.05
level increased significantly 24 h after the tachyzoites injection
and IgG antibody level increased significantly 72 h after the
injection.  The elevated level of anti-toxoplasma IgM antibody
after T. gondii  infection is a marker that can be considered as
an acute infection19,20.
In  this  study,  TNF-"  levels increased significantly after
3 days injections of 10 tachyzoites T.  gondii  strains of RH.
Some previous investigators also reported elevated TNF-"
levels in T. gondii 21-24. Increased  level  of  TNF-" commences
wi th  the  detect ion  of  toxoplasma paras i te
protein/glycosylphosphatidylinositol     (GPI)-anchored   by
toll-like receptors (TLRs). TLRs especially TLR2 and TLR4 that
are activated by GPI will trigger  macrophages  to produce
TNF-" and IL-1221. The T. gondii infection also specifically
stimulates TNF type 1 receptors (p55), so TNF-" can work as a
pro-inflammator25.
Seven days after intervention with C. longa extract, the
TNF-" levels decreased significantly compared with the
negative control group. The decreased in levels of TNF-" in
this study occurred because curcumin which is the main
component of  C. longa, can inhibit the production and action
of TNF-" in various ways15. It primarily suppresses the
expression of TNF-" through the down-regulation of NF-κB,
causing TLR2 and TLR 4 being unable to induce macrophages
to produce TNF-"25. Curcumin will also bind to myeloid
differentiation protein-2 (MD-2). This MD2-curcumin
compound will inhibit MyD 88, consequently inhibiting TLR2,
TLR 4, which results in inhibiting TLRs that stimulates
macrophages to produce TNF-"26.
The  excessive  TNF-"  level can cause cells damage such
as ischemic, hemorrhagic and necrotic cells9. If the TNF-"
excess levels happen  in  early pregnancy it can cause
abortion9. This study discovered that hemorrhagic and
necrotic  cells  is  not  found   in    intervention    groups   with
C. longa extract dose of 125 and 500 mg kgG1/day but in
intervention groups with spiramycin dose of 60 mgG1/day
(positive  control),  it  was  found  75%  and  intervention
groups with 0.2 mL distilled water it was found 100%. The
different  incidence   of   hemorrhagic and necrotic cells
among groups  intervened  with  C.  longa  and   spiramycin 
although TNF-" levels in these two groups did not differ
significantly, the researchers suspected to be associated with
antioxidant effects possessed by curcuma but need to be
further proven.
CONCLUSION
Curcuma  longa  extract  dose  of  125  mg  kgG1/day  for
7 days was   effective   to  decrease  the  TNF-"  levels and it
was effective  to  prevent  the  hemorrhagic  and   necrotic
cells  of   placental   tissue   of   early   pregnant  mice with
acute  toxoplasmosis.   Curcuma    longa    extract    dose  of
125 mg kgG1/day  can  be  considered as  an alternative
therapy in early pregnant women with acute toxoplasmosis
but further research is needed for the effectiveness and
toxicity of the first trimester pregnancy.
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SIGNIFICANCE STATEMENT
This  study   discovers   that   C.   longa  extract  dose  of
125 mg kgG1/day during 7 days effective to decrease TNF-"
level and to prevent cells damage placental tissue in early
pregnancy with acute toxoplasmosis. This investigation will
facilitate the researchers  to obtain an alternative drug for
early pregnancy with acute toxoplasmosis that many
researchers were not able to explore.
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